Esomeprazole: A review of its use in the management of gastric acid-related diseases in adults

Drugs

Volumn 68, Issue 11, 2008, Pages 1571-1607

  McKeage, Kate ^a,b   Blick, Stephanie K A ^a,b   Croxtall, Jamie D ^a,b   Lyseng Williamson, Katherine A ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Esomeprazole, general; Gastro oesophageal reflux, treatment; Helicobacter pylori infections, treatment; NSAID induced gastrointestinal damage, treatment; Oesophagitis, treatment; Zollinger Ellison syndrome, treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AMPRENAVIR PHOSPHATE; ANTACID AGENT; BENATOPRAZOLE; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; CYSTEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIAZEPAM; ESOMEPRAZOLE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; INDOMETACIN; LANSOPRAZOLE; METRONIDAZOLE; MOXIFLOXACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; QUINIDINE; RABEPRAZOLE; RANITIDINE; RIFABUTIN; RITONAVIR; SULFENAMIDE DERIVATIVE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; ENZYME INHIBITION; ESOPHAGUS MUCOSA; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIVER CELL DAMAGE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONEY; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NONHUMAN; PROTECTION; PROTON TRANSPORT; QUALITY ADJUSTED LIFE YEAR; REFLUX ESOPHAGITIS; RESPIRATORY TRACT INFECTION; REVIEW; SINGLE DRUG DOSE; STOMACH ACID SECRETION; STOMACH MUCOSA; STOMACH PH; STOMACH ULCER; ZOLLINGER ELLISON SYNDROME;

ADULT; ANTI-ULCER AGENTS; DUODENAL ULCER; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE; PROTON PUMP INHIBITORS; STOMACH ULCER; ZOLLINGER-ELLISON SYNDROME;

HELICOBACTER PYLORI;

EID: 47349127413     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868110-00009     Document Type: Review

References (143)

1. Miner Jr P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 Dec; 98 (12): 2616-20
2. Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease - what are the unmet clinical needs? Aliment Pharmacol Ther 2006; 23 Suppl. 2: 9-22
3. Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62 (10): 1503-38
4. AstraZeneca. Nexium (esomeprazole magnesium) prescribing information: delayed-release capsules and delayed-release oral suspension [online]. Available from URL: http://www.astrazeneca-us.com/pi/Nexium [Accessed 2008 Jan 30]
5. Wilder-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol 2007 Feb; 42 (2): 157-64
6. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24
7. Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007 Mar; 25 (5): 617-28
8. Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005 Jul 15; 22 (2): 129-34
9. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004 Oct; 60 (8): 531-9
10. Simon B, Müller P, Pascu O, et al. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003 Jul; 15 (7): 791-9
11. Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002 May; 47 (5): 954-8
12. Goldstein JL, Miner Jr PB, Schlesinger PK, et al. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2006 Apr 15; 23 (8): 1189-96
13. Wilder-Smith C, Backlund A, Eckerwall G, et al. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomised, dose-response study. Clin Drug Investig 2008; 28 (6): 333-43
14. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther 2007 Jan 15; 25 (2): 197-205
15. Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004 May 15; 19 (10): 1105-10
16. Frazzoni M, Manno M, De Micheli E, et al. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. Dig Liver Dis 2006 Feb; 38 (2): 85-90
17. Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, et al. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003; 68 (4): 184-8
18. Röhss K, Wilder-Smith C, Naucler E, et al. Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig 2004; 24 (1): 1-7
19. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily: a randomized, two-way cross-over study. Aliment Pharmacol Ther 2005 Apr 15; 21 (8): 963-7
20. Li ZS, Zhan XB, Xu GM, et al. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial. J Gastroenterol Hepatol 2007 Jun; 22 (6): 815-20
21. Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005 Mar 1; 21 (5): 575-82
22. Galmiche JP, Bruley Des Varannes S, Ducrott́ P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004 Mar 15; 19 (6): 655-62
23. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005 Sep; 100 (9): 1949-56
24. Genta RM, Rindi G, Fiocca R, et al. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gascotroenterol 2003 Jun; 98 (6): 1257-65
25. Vieth M, Kulig M, Leodolter A, et al. Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus. Aliment Pharmacol Ther 2006 Jan 15; 23 (2): 313-9
26. Hritz I, Herszenyi L, Molnar B, et al. Long-term omeprazole and esomeprazole treatment does not significantly increase gastric epithelial cell proliferation and epithelial growth factor receptor expression and has no effect on apoptosis and p53 expression. World J Gastroenterol 2005 Aug 14; 11 (30): 4721-6
27. Gatta L, Perna F, Figura N, et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemother 2003 Feb; 51 (2): 439-42
28. Koch TR, Petro A, Darrabie M, et al. Effects of esomeprazole magnesium on nonsteroidal anti-inflammatory drug gastropathy. Dig Dis Sci 2005 Jan; 50 (1): 86-93
29. Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40 (6): 411-26
30. Hassan-Alin M, Andersson T, Bredberg E, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665-70
31. Hassan-Alin M, Andersson T, Niazi M, et al. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 2005 Jan; 60 (11): 779-84
32. Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol 2007 Sep; 64 (3): 386-90
33. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7
34. AstraZeneca UK Limited. Nexium 20mg & 40mg tablets [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displaydoc. asp?documentid=1809 [Accessed 2008 Feb 26]
35. Bladh N, Blychert E, Johansson K, et al. A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. Clin Ther 2007 Apr; 29 (4): 640-9
36. Sostek MB, Chen Y, Skammer W, et al. Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing. Aliment Pharmacol Ther 2003 Sep 15; 18 (6): 581-6
37. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 2002; 58: 453-58
38. Äbelö A, Andersson T, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28 (8): 966-72
39. Schwab M, Klotz U, Hofmann U, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005 Dec; 78 (6): 627-34
40. Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001; 40 (2): 145-50
41. 14C]omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986; 40 (3): 344-51
42. Sjövall H, Björnsson E, Holmberg J, et al. Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 2002 May; 14 (5): 491-6
43. Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, et al. Lack of pharmacokinetic interaction between esomeprazole and the nonsteroidal anti-inflammatory drugs naproxen and rofecoxib in healthy subjects. Clin Drug Investig 2005; 25 (11): 731-40
44. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008; 47 (2): 75-89
45. McCabe SM, Smith PF, Ma Q, et al. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol 2007; 3 (2): 197-207
46. Shelton MJ, Ford SL, Borland J, et al. Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr 2006 May; 42 (1): 61-7
47. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20
48. Bardhan KD, Achim A, Riddermann T, et al. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007 Jun 15; 25 (12): 1461-9
49. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002 Mar; 97 (3): 575-83
50. Fennerty MB, Johanson JF, Hwang C, et al. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005 Feb; 21 (4): 455-63
51. Gillessen A, Beil W, Modlin IM, et al. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004 Apr; 38 (4): 332-40
52. Howden CW, Ballard II ED, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22 (2): 99-109
53. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005 Mar; 21 (6): 739-46
54. Lightdale CJ, Schmitt C, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci 2006 May; 51 (5): 852-7
55. Schmitt C, Lightdale CJ, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006; 51 (5): 844-50
56. DeVault KR, Johanson JF, Johnson DA, et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006 Jul; 4 (7): 852-9
57. Lauritsen K, Devière J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003 Feb; 17 (3): 333-41
58. Goh KL, Benamouzig R, Sander P, et al. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol 2007 Mar; 19 (3): 205-11
59. Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005 Nov; 22 (9): 803-11
60. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000 Oct; 14 (10): 1249-58
61. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001 Mar; 96 (3): 656-65
62. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004 Aug; 20 (4): 413-21
63. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003 Sep; 18 (6): 587-94
64. Glatzel D, Abdel-Qader M, Gatz G, et al. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion 2007; 75 Suppl. 1: 69-78
65. Mönnikes H, Pfaffenberger B, Gatz G, et al. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion 2007; 75 Suppl. 1: 62-8
66. Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004 Sep; 20 (6): 657-65
67. Johnsson F, Hatlebakk JG, Klintenberg AC, et al. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn. Scand J Gastroenterol 2003 Apr; 38 (4): 347-53
68. Johnson DA, Banjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001 Jan; 96 (1): 27-34
69. Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001 Jul; 15 (7): 927-35
70. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003 Nov; 18 (9): 875-82
71. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002 Aug; 14 (8): 857-63
72. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom contol in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of on demand therapy for 6 months. Aliment Pharmacol Ther 2001 Mar; 15 (3): 347-54
73. Sjöstedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005 Aug; 22 (3): 183-91
74. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic anti-reflux surgery to esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut. Epub 2008 May
75. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 Aug; 45 (2): 172-80
76. Chey W, Huang B, Jackson RL. Lansoprazole and esomeprazole in symptomatic GERD: a double-blind, randomized, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003; 23 (2): 69-84
77. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006 Sep; 24 (5): 743-50
78. Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006 Dec; 4 (12): 1452-8
79. Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 2007 Oct; 26 (8): 1101-11
80. Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005 Dec; 100 (12): 2650-7
81. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006 Apr; 101 (4): 701-10
82. Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005 May; 100 (5): 1028-36
83. Hawkey CJ, Talley NJ, Scheiman JM, et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther 2007; 9 (1): R17
84. Yeomans N, Lanas A, Labenz J, et al. Prevention of low dose aspirin-associated gastroduodenal ulcers and upper gastrointestinal symptoms in patients receiving esomeprazole 20 mg per day [abstract no. P2307]. Eur Heart J 2006 Aug; 27 Suppl. 1: 382
85. Tulassay Z, Kryszewski A, Dite P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001; 13 (12): 1457-65
86. Wu IC, Wu DC, Hsu PI, et al. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection. Helicobacter 2007 Dec; 12 (6): 633-7
87. Veldhuyzen van Zanten S, Lauritsen K, Delchier J-C, et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000 Dec; 14 (12): 1605-11
88. Veldhuyzen van Zanten S, Machado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2003 Jun; 17 (11): 1381-7
89. Laine L, Fennerty B, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol 2000 Dec; 95 (12): 3393-8
90. Hsu PI, Lai KH, Wu CJ, et al. High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection. Eur J Clin Invest 2007 Sep; 37 (9): 724-30
91. Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005 Nov; 100 (11): 2387-92
92. Subei IM, Cardona HJ, Bachelet E, et al. One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healing in Helicobacter pylori-positive patients. Dig Dis Sci 2007 Jun; 52 (6): 1505-12
93. Tulassay Z, Stolte M, Sjölund M, et al. Effect of esomeprazole triple therapy on Helicobacter pylori eradication rates, gastric ulcer healing, and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol 2008 Jun; 20 (6): 526-36
94. Gisbert JP, Domínguez-Muñoz A, Domínguez- Martín A, et al. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? Am J Gastroenterol 2005 Sep; 100 (9): 1935-40
95. Vakil N. Helicobacter pylori treatment: a practical approach. Am J Gastroenterol 2006; 101: 497-9
96. Miehlke S, Schneider-Brachert W, Kirsch C, et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2008; 13 (1): 69-74
97. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007 Dec; 102 (12): 2648-54
98. Talley NJ, Vakil N, Lauritsen K, et al. Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response? Aliment Pharmacol Ther 2007 Sep; 26 (5): 673-82
99. van Zanten SV, Flook N, Talley NJ, et al. One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study. Aliment Pharmacol Ther 2007 Sep; 26 (5): 665-72
100. Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104 (3): 252-8
101. Wahlqvist P, Karlsson M, Johnson D, et al. Relationship between symptom load of gastroesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther 2008 May; 27 (10): 960-70
102. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161: 45-52
103. Hansen AN, Bergheim R, Fagertun H, et al. Long-term management of patients with symptoms of gastro-oesophageal reflux disease: a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract 2006 Jan; 60 (1): 15-22
104. Pace F, Negrini C, Wiklund I, et al. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesphageal reflux disease. Aliment Pharmacol Ther 2005; 22: 349-56
105. Johnson DA, Orr WC, Crawley JA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005 Sep; 100 (9): 1914-22
106. Wahlqvist P, Sörng̊ard H. Cost-effectiveness of esomeprazole versus generic omeprazole in the acute treatment of reflux esophagitis in Sweden [abstract no. PG19]. Value Health 2005 Nov-Dec; 8 (6): A121. Plus poster presented at the Internation-al Society for Pharmacoeconomics and Outcomes Research 8th Annual European Congress; 2005 Nov 6-8; Florence
107. Wahlqvist P, Reinhold T. Cost-effectiveness of esomeprazole versus generic omeprazole in the acute treatment of reflux esophagitis in Germany [abstract no. PG110]. Value Health 2006 Nov-Dec; 9 (6): A244. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research 9th Annual European Congress; 2006 Oct 28-31; Copenhagen
108. Zeramdini R, Baxter G, Conway P. Economic evaluation of lansoprazole orodispersible tablets compared to esomeprazole tablets in the acute management of reflux oesophagitis [abstract no. MON-G-53]. Gut 2005; 54 Suppl. VII: A96
109. Wahlqvist P, Fernström M, Määttä P, et al. Esomeprazole is cost-effective compared with pantoprazole in the acute and maintenance treatment of reflux esophagitis in Finland [abstract no. PG16]. Value Health 2005 Nov-Dec; 8 (6): A120. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research 8th Annual European Congress; 2005 Nov 6-8; Florence
110. Mason J, Lloyd AC, Holman AJ, et al. Economic evaluation comparing lansoprazole and esomeprazole in the acute management of uninvestigated dyspepsia [abstract no. PG14]. Value Health 2007 Nov-Dec; 10 (6): A352
111. Lee KK, Lee VWY, Chan FK. Cost-effectiveness of triple therapies of esomeprazole and rabeprazole for H. pylori eradication in the public sector of Hong Kong [abstract no. G14]. Value Health 2006 Nov-Dec; 9 (6): A190
112. Meineche-Schmidt V, Hauschildt Juhl H, Østergaard JE, et al. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care. Aliment Pharmacol Ther 2004 Apr; 19 (8): 907-15
113. Hansen AN, Wahlqvist P, Jørgensen E, et al. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment stratetries in a general medical practitioners setting. Int J Clin Pract 2005 Jun; 59 (6): 655-64
114. Hughes DA, Bodger K, Bytzer P, et al. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics 2005; 23 (10): 1031-41
115. Jönsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22 Suppl. 4: 5-10
116. Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008; 31 (7): 627-36
117. US FDA Center for Drug Evaluation and Research. Early communication about an ongoing safety review: omeprazole (Prilosec) and esomeprazole (Nexium) [online]. Available from URL http://www.fda.gov/CDER/Drug/early_comm/ omeprazole_esomeprazole.htm [Accessed 2007 Dec 10]
118. US FDA. FDA approves Nexium for use in children ages 1-11 years [online]. Available from URL: http://www.fda.gov/consumer/updates/nexium 030308.html [Accessed 2008 Mar 14]
119. Croxtall JD, Perry CM, Keating GM. Esomeprazole: in gastroesophageal reflux disease in children and adolescents. Pediatr Drugs 2008; 10 (3): 199-205
120. Ferguson DD, DeVault KR. Medical management of gastroesophageal reflux disease. Expert Opin Pharmacother 2007; 8 (1): 39-47
121. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (review). Cochrane Database Syst Rev 2006; (3): CD002095
122. Dent J, El-Serag HB, Wallander M-A, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 May; 54 (5): 710-7
123. Labenz J, Morgner-Miehlke A. An update on the available treatments for non-erosive reflux disease. Expert Opin Pharmacother 2006; 7 (1): 47-56
124. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan; 100 (1): 190-200
125. National Institute for Clinical Excellence. Dyspepsia: management of dyspepsia in adults in primary care [online]. Available from URL: http://www.nice.org.uk/guidance/index.jsp?action=download&o=29458 [Accessed 2008 Mar 3]
126. Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol 2004; 94: 106-11
127. Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008 Feb; 103 (2): 267-75
128. Metz DC, Inadomi JM, Howden CW, et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 2007 Mar; 102 (3): 642-53
129. Pace F, Tonini M, Pallotta S, et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken "on demand". Aliment Pharmacol Ther 2007 Jul; 26 (2): 195-204
130. Morgner A, Miehlke S, Labenz J. Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Expert Opin Pharmacother 2007 May; 8 (7): 975-88
131. Hirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2 (3): 207-23
132. Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23 (5): 432-4
133. Spiegel BMR, Chiou C-F, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005; 53 (2): 185-97
134. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Heliobacter pylori infection: the Mastricht III Consensus Report. Gut 2007; 56: 772-81
135. Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2006; 7 (2): 169-75
136. Talley NJ, Vakil N, Practice Parameters Committee for the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100: 2324-37
137. Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127 (5): 1329-37
138. Wahlqvist P, Brook RA, Campbell SM, et al. Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease. J Occup Environ Med 2008 Jan; 50 (1): 25-31
139. Dean BB, Crawley JA, Schmitt CM, et al. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003; 17: 1309-17
140. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia. Arch Intern Med 2007; 167: 950-55
141. Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296 (24): 2947-53
142. Dial S, Delaney JAC, Barkun AN, et al. Use of acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294 (23): 2989-95
143. Coron E, Hatlebakk JG, Galmiche J-P. Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol 2007 Jul; 23 (4): 434-9